Medpace (NASDAQ:MEDP) Trading Down 0.3%

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report)'s share price fell 0.3% on Wednesday . The company traded as low as $386.42 and last traded at $387.29. 39,505 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 247,935 shares. The stock had previously closed at $388.35.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. StockNews.com upgraded Medpace from a "hold" rating to a "buy" rating in a research note on Tuesday, April 23rd. Jefferies Financial Group upgraded Medpace from a "hold" rating to a "buy" rating and raised their target price for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. UBS Group upgraded Medpace from a "neutral" rating to a "buy" rating and raised their target price for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Robert W. Baird raised their target price on Medpace from $446.00 to $454.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 24th. Finally, Guggenheim raised their target price on Medpace from $453.00 to $464.00 and gave the stock a "buy" rating in a research note on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, Medpace has an average rating of "Moderate Buy" and a consensus price target of $443.00.

Medpace Stock Performance

The stock has a 50 day simple moving average of $398.32 and a two-hundred day simple moving average of $328.94. The firm has a market cap of $12.33 billion, a PE ratio of 40.56, a price-to-earnings-growth ratio of 1.99 and a beta of 1.38.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.75. The company had revenue of $511.00 million for the quarter, compared to analysts' expectations of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. Medpace's revenue was up 17.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.27 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Insider Transactions at Medpace

In other news, major shareholder Medpace Investors, Llc sold 13,988 shares of Medpace stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the sale, the insider now owns 5,525,959 shares of the company's stock, valued at approximately $2,135,175,298.01. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Medpace news, major shareholder Medpace Investors, Llc sold 13,988 shares of the business's stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total value of $5,404,823.32. Following the sale, the insider now owns 5,525,959 shares of the company's stock, valued at $2,135,175,298.01. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 102 shares of the business's stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares in the company, valued at approximately $6,117,943. The disclosure for this sale can be found here. Insiders have sold a total of 204,442 shares of company stock worth $82,702,867 in the last ninety days. Insiders own 20.30% of the company's stock.

Institutional Trading of Medpace

A number of large investors have recently modified their holdings of the stock. RiverPark Advisors LLC acquired a new position in shares of Medpace during the fourth quarter worth $26,000. Contravisory Investment Management Inc. purchased a new position in Medpace during the fourth quarter worth about $26,000. Rise Advisors LLC purchased a new position in Medpace during the first quarter worth about $27,000. Mather Group LLC. purchased a new position in Medpace during the first quarter worth about $28,000. Finally, FinTrust Capital Advisors LLC purchased a new position in Medpace during the third quarter worth about $30,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.